新辅助化疗对骨肉瘤多药耐药相关蛋白表达的影响  

Influence of Neoadjuvant Chemotherapy on the Expression of Multidrug Resistance-associated Proteins in Osteosarcoma

作　　者：李晨 岳付桥 徐翠芳 张树桧[2] 

机构地区：[1]安徽阜阳创伤医院,安徽阜阳236000 [2]郑州大学第二附属医院骨科,河南郑州450000

出　　处：《现代生物医学进展》2012年第20期3921-3923,3927,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨不同新辅助化疗方案对多药耐药相关蛋白在骨肉瘤组织中表达的影响。方法:采用RP-PCR技术以及免疫组化技术检测48例骨肉瘤患者在不同新辅助化疗方案实施前后多药耐药相关蛋白在mRNA以及蛋白水平的表达变化。结果:在同一新辅助化疗方案实施前后以及不同新辅助化疗方案之间,肿瘤组织的多药耐药蛋白的mRNA及蛋白表达均无显著性差异。结论:不同新辅助化疗方案的实施对骨肉瘤多药耐药蛋白表达的影响有限,其多药耐药性可能主要决定于肿瘤本身,检测多药耐药蛋白的表达有利于制定个体化化疗方案。Objective： To explore the effect of different neoadjuvant chemotherapy on the expression of multidrug resistance-associated protein in osteosareoma. Methods： RP-PCR and immunohistochemical techniques were used to detect the expression of multi-drug resistance-associated protein mRNA and protein in 48 cases of osteosarcoma patients before and after the implementation of neoadjuvant chemotherapy. Results： There was no significant difference in MDR expression between before and after neoadjuvant chemotherapy, and there was no difference between two types of neoadjuvant chemotherapy regimens. Conclusion： The effect of implementation of different neoadjuvant chemotherapies is very limited on expression of multidrug resistance protein in osteosarcoma. The multi-drug resistance of this tumour may be mainly determined by itself. Detection of the multidrug resistance protein expression will facilitate the development of individual chemotherapy.

关 键 词：骨肉瘤 多药耐药相关蛋白 新辅助化疗 

分 类 号：R738[医药卫生—肿瘤]